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Differential scanning calorimetry (DSC) was used as screening technique for assessing compatibility 
between dika fat and drug substances. Dika fat was found to be compatible with aspirin, ascorbic acid, 
paracetamol, sulphanilamide, phenylpropanolamine hydrochloride, bromopheniramine maleate, 
chlorpheniramire maleate, diazepam, phenobarbital, phenobarbital sodium, phenylpropanolamine 
hydrochloride and propranolol hydrochloride. It appears that dika fat can be used as a formulation aid in 
medicinal or veterinary products containing any of these substances. It was found that dika fat may 
interact with ephedrine hydrochloride, norgestrel and atropine sulphate.        
 




These authors first reported the use of dika fat in 
the formulation of pharmaceutical dosage forms as 
tablet lubricant (Udeala et al, 1980; Onyechi and 
Udeala, 1990). We also reported the use of the fat 
in the preparation of sustained release tablets 
(Onyechi and Udeala, 1988). Other workers have 
since described the use of dika fat in the formulation 
of other dosage forms (Ofoefule et al., 1997; 
Ofoefule and Chukwu, 2001). Since our first report, 
and despite the increasing use of dika fat as a 
formulation aid for medicinal and cosmetic products, 
there has been no report of the study of the 
compatibility of dika fat with classes of drugs and 
formulation excpients.    
Dika fat is a solid vegetable oil extracted 
from the kernels of Irvingia gabonensis var 
gabonensis and var excelsia. Dika fat exhibits 
excellent storage stability at room temperature 
(Udeala et al., 1980). The fat is generally used for 
food and is therefore easily available. 
The compatibility of a drug substance with 
excipients used in pharmaceutical formulations is 
determined by preformulation studies. Several 
techniques have been used to study drug-drug and 
drug–excipent interactions: thin layer 
chromatography, diffuse reflectance spectroscopy, 
tristimulus reflectance and quantitative assay after 
isothermal stress, differential thermal analysis, DTA 
and differential scanning calorimetry.  
A differential scanning calorimeter 
measures the difference in heat flows to a sample 
and a reference, which are subjected to the same 
temperature programme. DSC measurements 
provide information on thermal effects that are 
characterized by an enthalpy change and by the 
temperature range, such as melting behaviour, 
crystallization, solid-solid transitions and chemical 
reactions (Bottom, 2001) 
In pharmaceutical systems DSC and DTA 
have been used for the determination and 
estimation of impurities (Van Doreen and Mueller, 
1984), identification of polymorphic forms and 
solvates (Giron, 1995; Giron, 1998), assessment of 
molecular interaction between solid components of 
pharmaceuticals (Mura et al, 1998; McDaid et al., 
2003) and for the rapid evaluation of the 
compatibility of drug substances with excipients (El-
Shattaway et al, 1982; Botha and Lother, 1990; 
Mura et al., 2005; Balestrieri et al., 1996). In the 
present investigation computer mediated differential 
scanning calorimetry was used to study the 
compatibility of dika fat with some drugs. We have 
compared the DSC thermograms of 1:1 mixtures of 
dika fat and the drugs with those of the 
components.                                                                                           
 
Materials and Methods  
 
The following materials were used aspirin (Merck, 
USA), ascorbic acid (Roche, USA), 
bromopheniramine maleate (Hexagon, USA), 
chlorphenirarnine maleate (Hexagon, USA), 
diazepam (Roche, USA), paracetamol (Halewood, 
England), phenobarbital (Merck, USA), 
phenobarbital sodium (Merck, USA), propranolol 
hydrochloride (Merck, USA), phenylpropanolanine 
hydrochloride (Merck, USA), sulphanilamide 
(Merck, USA) norgestrel (Wet, USA), atropine 
sulphate (Merck, USA) and ephedrine hydrochloride 
(Sigma, USA).  
 
Differential scanning calorimetry: Thermal 
analyses were performed on dika fat, pure drug and 
1:1 (w/w) physical mixtures of dika fat and named 
drugs respectively. Samples (2-8 mg) were weighed 
and after being finely powdered were encapsulated 
in flat-bottomed aluminum pans with crimped-on 
lids. Thermal curves were obtained using a Perkin-
Elmer DSC-4 differential scanning calorimeter 
(Perkin-Elmer Corporation, Norwalk, CT, USA) 
equipped with a Bascom Turner Recorder and Data 
Acquisition System (Bascom Turner Instruments, 
MT, USA). A model DSC Intracooler (Perkin Elmer 
Corporation, Norwalk, CT, USA) provided a 
convenient means of cooling the sample holder 
enclosure block of the calorimeter.  
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Thermograms were obtained at a constant heating 
range setting of 20 mcal per minute, in an 
atmosphere of nitrogen and recorded at a constant 
chart speed of one inch per minute. The individual 
substances and 1:1 mixtures of drug and dika fat 
prepared were heated over the temperature range 
20 to 2200C.  
  
Results and Discussion 
 
The DSC thermograms of the dika fat samples used 
in this study are shown in Figure 1. Data from the 
endothermic profiles are presented in Table 1. The 
endothermic profiles for unrefined dika fat samples 
from var excelsia (Fig. 1 a) showed a melting 
endothermic peak with a transition temperature 
range from 28 – 600C and an average maximum 
peak of transition at 460C. The refined fat sample 
from the same var excelsia (Fig 1b) showed a 
melting endothermic peak with a transition 
temperature range from 32 – 520C and an average 
maximum peak of transition at 480C. The 
endothermic profile for unrefined dika fat from var 
gabonensis (Fig. 1c) showed a melting endothermic 
peak with a transition temperature range from 28 – 
520C and an average maximum peak of transition at 
450C. The endothermic profile for refined dika fat 
from var gabonensis (Fig. 1d) also showed a 
melting endothermic peak with a transition 
temperature range from 32 – 480C and an average 
maximum peak of transition at 470C. Endothermic 
profiles of dika fat samples derived from var 
excelsia and var gabonensis showed no real 





















DSC thermograms were generated for 
physical mixtures of processed (refined) and 
unprocessed (unrefined) samples of dika fat and 
both aspirin and ascorbic acid. The purpose was to 
determine the effect, if any, of the purification 
procedure adopted for dika fat, on the thermal 
behaviour of either aspirin or ascorbic acid, and the 
dika fat sample used. Data from the endothermic 
profiles are presented in Table 2. The endothermic 
profiles for aspirin showed an endotherm with a 
transition temperature range from 132 – 150 0C and 
an average maximum peak of transition at 145 0C. 
This transition peak corresponds to the melting of 
aspirin. The transition temperature range of 141 – 
144 0C is official in the European Pharmacopoeia 
(1969). The endothermic profile for dika fat showed 
a melting endothermic peak with a transition 
temperature range from 28 – 60 0C and an average 
maximum peak of transition at 460C. The 
endothermic profile of the mixture of aspirin and 
both refined and unrefined dika fat combined the 
features characteristic of the endothermic profiles of 
each component. No interaction between dika fat 
and aspirin occurred. Bottom (2001) stated that 
incompatibility is highly improbable if the 
endothermic profiles of a mixture are a simple 
superposition of those of the components. 
Data from the endothermic profiles for 
physical mixtures of ascorbic acid and dika fat 
derived from both Irvingia gabonensis var excelsia 
and var gabonensis are also presented in Table 2.  
The endothermic profile for ascorbic acid showed 
an endotherm with a transition temperature range 
from 192 – 204 0C and an average maximum peak 
of transition at 1980C. This transition peak 
corresponds to the melting of ascorbic acid. The 
melting temperature range for ascorbic acid 
obtained was 192 – 2040 C (Merck Index, 1976a; 
Clarke, 1969). The melting temperature range 
obtained in this work (192 – 204 0 C) was within the 
range reported. Endothermic profiles of the mixtures 
of ascorbic acid with processed and unprocessed 
dika fat indicated the same double peaked 
endothermic transitions corresponding to the peaks 
of the individual components. Incompatibility 
between ascorbic acid and dika fat is therefore 
highly improbable. DSC thermograms of dika fat 
samples derived from the var excelsia and var 
gabonensis showed no real difference between the 
two sources in endothermic profiling per se and with 
both aspirin and ascorbic acid. Therefore only 
processed dika fat derived from Irvingia gabonensis 





  Data from the endothermic profiles of other 
drugs investigated in this study are presented in 
Table 3.  The drugs were: bromopheniramine 
maleate, chlorphenirarnine maleate, diazepam, 
paracetamol, phenobarbital, phenobarbital sodium, 
phenylpropanolamine hydrochloride, propranolol 
hydrochloride, ephedrine hydrochloride, norgestrel 
and atropine sulphate.  
D 
Fig. 1: DSC thermograms for fat
from Irvingia gabonensis , a, var 
excelsia (unrefined); b, var 
excelsia (refined); c, var 
gabonensis (unrefined) and d,
var gabonensis (refined)








 Bottom (2001) suggested that 
pharmaceutical preparations can be rapidly 
investigated by DSC for incompatibility by 
comparing the results for the individual components 
and the mixture with each other. If the mixture 
exhibits thermal effects that are not apparent in the 
individual components, he suggested that that is an 
indication of interaction.       
The endothermic profile for the mixture of 
dika fat and bromopheniramine maleate combined 
the features characteristic of the thermal curves of 
dika fat and bromopheniramine maleate. Interaction 
between dika fat and bromopheniramine maleate is 
therefore improbable.  
  The endothermic profile for the mixture of 
dika fat and chlorpheniramine maleate combined 
the features characteristic of the thermal curves of 
dika fat and chlorpheniramine maleate.  
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Table 1: Transition temperature obtained from endothermic profiles of dika fat samples by differential 
scanning calorimetry 







Unrefined Irvingia gabonensis var excelsia   28-60 46 Melting endotherm 
Refined Irvingia gabonensis var excelsia   32-52 48 Melting endotherm 
Unrefined Irvingia gabonensis var 
gabonensis   28-52 45 Melting endotherm 
Refined Irvingia gabonensis var excelsia   32-48 47 Melting endotherm 
 
Table 2: Endothermic profiles of dika fat with aspirin and ascorbic acid combinations using differential 
scanning calorimetry 
Transition temperature range (0 C)  Dika fat/drug mixture 
20-60 60-100 100-140 140-180 180-220 
Unrefined Dika fat from Irvingia gabonensis var gabonensis 28-52     
Aspirin   132-150 132-150  
1:1 Aspirin-unrefined dika fat from Irvingia gabonensis var 
gabonensis mix  30-56  130-152 130-152  
Refined Dika fat from Irvingia gabonensis var gabonensis 32-48     
1:1 Aspirin-refined dika fat from Irvingia gabonensis var 
gabonensis mix 33-55  132-150 131-151  
Unrefined Dika fat from Irvingia gabonensis var excelsia 28-60     
1:1 Aspirin-unrefined dika fat from Irvingia gabonensis var 
excelsia mix 29-60  132-150 132-150  
Refined Dika fat from Irvingia gabonensis var excelsia 32-52     
1:1 Aspirin-refined dika fat from Irvingia gabonensis var 
excelsia mix 34-51  134-149 134-149  
Ascorbic acid     192-204 
1:1 Ascorbic acid-unrefined dika fat from Irvingia 
gabonensis var gabonensis mix 29-60    190-206 
1:1 Ascorbic acid-refined dika fat from Irvingia gabonensis 
var gabonensis mix 25-60    191-205 
1:1 Ascorbic acid-unrefined dika fat from Irvingia 
gabonensis var excelsia mix 26-60    189-208 
1:1 Ascorbic acid-refined dika fat from Irvingia gabonensis 
var excelsia mix 27-56    191-206 
 
Interaction between dika fat and chlorpheniramine 
maleate is also improbable.   
The mixture of dika fat and diazepam 
exhibited thermal effects apparent in the individual 
components; this is an indication of no interaction. 
Donahue (1975) reported a melting endotherm at 
1280C for diazepam by DSC. The melting range for 
diazepam is reported in NF XIII as 131–135 0C. 
Therefore, the result obtained in the present 
investigation showed there was no incompatibility 
between this drug and dika fat. 
The endothermic profile for the mixture of 
dika fat and paracetamol also combined the 
features characteristic of the thermal curves of dika 
fat and paracetamol. Interaction between dika fat 
and paracetamol is therefore highly improbable. 
The endothermic profile for the mixture of 
dika fat and phenylpropanolamine hydrochloride is 
a superimposition of the thermal curves of dika fat 
and phenylpropanolamine hydrochloride. Interaction 
between dika fat and phenylpropanolamine 
hydrochloride is therefore improbable. 
The endothermic profiles for the mixture of 
dika fat and propranolol hydrochloride combined the 
features characteristic of the endothermic profiles of 
dika fat and propranolol hydrochloride. Interaction 
between dika fat and propranolol hydrochloride is 
improbable. 
The thermal curve for the mixture of dika 
fat and phenobarbital sodium combined the features 
characteristic of the thermal curves of dika fat and  
 
phenobarbital sodium. This is an indication of no 
interaction between dika fat and phenobarbital 
sodium. 
In the endothermic profile of the mixture of 
dika fat and phenobarital, some changes were 
discernible when compared with the profiles of the 
component materials. The first endotherm 
corresponding to phenobarbital was broadened and 
was shifted to higher temperatures. This contrasted 
with the same endotherm on the endothermic profile 
of pure phenobarbital. The second endotherm 
indicating the melting of dika fat was still 
identifiable. Phenobarbital is known to exhibit 
polymorphism. It is usual practice to subject 
samples that show polymorphism to some form of 
pretreatment prior to DSC. This ensures that only a 
known polymorphic form is present. The sample of 
phenobarbital used in this investigation was not 
pretreated. The various polymorphic forms were 
present in the sample. The changes which occurred 
in the endothermic profile of the mixture of dika fat 
and phenobarbital resulted from the presence of the 
various polymorphic forms of the drug. However, 
from stability considerations, it is to be assumed 
that incompatible interaction between dika fat and 
the drug is probable.  
The endothermic profile for pure norgestrel 
showed a melting endotherm from 205 – 2100C. In 
the endothermic profile for a mixture of norgestrel 
with dika fat an endotherm that indicated the 
melting of dika fat was seen.  
Onyechi and Udeala 468
Table 3:  Data from thermal curves of named drugs and 1:1 physical mixture of dike fat and named drugs 
Transition temperature 
range in 0 Co 
Peak transition 





1:1 Mix of 
pure drug 
and dike fat 
Pure 
drug 
1:1 Mix of 
drug and 
dika  fat 
Remarks 
Diazepam 128-140 120-136 130 130  Endothermic transition of 1300 C indicative of 
melting. No incompatibility with dika fat. 
 Bromopheniramine 
maleate 
130-140 138-142 136 136  Endothermic transition of 1360 C indicative of 
melting. No incompatibility with dika fat. 
Chlropheniramine 
maleate 
132-144 130-144 136 136  Endothermic transition of 1360 C indicative of 
melting. No incompatibility with dika fat. 
 Paracetamol  160-176 160-176 172 172  Endothermic transition of 1710 C indicative of 
melting. No incompatibility with dika fat. 
Phenobarbital 
Sodium 
190-220 188-220 194 194 Endothermic transition of 1300 C indicative of 
melting. Exhibiting polymorphism.  No 
incompatibility with dika fat. 
Phenylpropanolamine 
hydrochloride 
188-198 188-200 195 195 Endothermic transition of 1950 C indicative of 
melting. Exhibiting polymorphism.  No 
incompatibility with dika fat. 
Propanol 
hydrochloride  
160-175 160-175 164 164 Endothermic transition of 1950 C indicative of 
melting. Exhibiting polymorphism.  No 
incompatibility with dika fat. 
Sulfanilamide 166-174 165-174 166 166 Endothermic transition of 1950 C indicative of 
melting. Exhibiting polymorphism.  No 
incompatibility with dika fat. 
Norgestrel 200-220 190-220 210 209  Endothermic transition of 2000 C indicating 
melting. Melting endotherm shifted to lower 
temperature in mix with the fat. Probable 
interaction dika fat. 
Atropine Sulphate 196-210 Obliterated 194 Obliterated Endothermic transition of 1940 C indicating melting. 
Melting peak obliterated in mixture with dika fat.  
Probable interaction with dika fat                       
Ephedrine 
hydrochloride 
119-140 Obliterated 132 obliterated Endothermic transition of 1940 C indicating melting. 
Melting peak obliterated in mixture with dika fat.  
Probable interaction with dika 
 
The endotherm corresponding to the melting of 
norgestrel was also identifiable. However, the 
transition temperature range was broadened and 
shifted to lower temperatures. De Angelis (1969) 
reported that norgestrel showed a sharp 
endothermic peak indicating melting at 209oC. 
Melting temperature ranges from 206 - 2070C have 
been reported (Merck Index, 1976b). The melting 
temperature range obtained in this work 205 - 
2100C is similar to reported values. However the 
change in thermal behaviour of norgestrel in the 
presence of dika fat indicated probable interaction 
between the two under the experimental conditions. 
Data from the endothermic profile of a 
mixture of dika fat and atropine sulphate is included 
in Table 3. An endotherm indicating the melting of 
dika fat is shown. The first endotherm 
corresponding to atropine sulphate was broadened 
and shifted to higher temperatures. The second 
endotherm corresponding to the melting of atropine 
sulphate was completely obliterated. Such a change 
in the thermal behaviour of atropine sulphate when 
mixed with dika fat indicated incompatible 
interaction.  
The endothermic profile of a physical 
mixture of dika fat and ephedrine hydrochloride 
showed that the first endotherm indicating the 
melting of dika fat shifted to higher temperatures. 
The second endotherm corresponding to the 
melting of ephedrine hydrochloride was completely 
obliterated. Such a change in the thermal behaviour 
of ephedrine hydrochloride when mixed with dika fat 
indicated incompatible interaction.  
Overall data presented in Table 3, from the 
endothermic profiles of mixtures of dika fat with 
various drugs, enabled a prediction of possible 
interaction between dika fat and the different drugs.    
 
Conclusion: The drugs investigated in the study 
fall into three categories. In the first group are drugs 
which showed no evidence of incompatibility with 
dika fat. The endothermic profiles of physical 
mixtures of the drugs with dika fat combined the 
peaks characteristic of the individual components. 
The profiles of the mixtures are a simple 
superposition of those of the components. The 
drugs in this group included: aspirin, ascorbic, 
paracetamol, phenylpropanolamine hydrochloride, 
bromopheniramine maleate, chlorpheniramire 
maleate and diazepam. 
Drugs belonging to a second group did not 
show conclusive evidence of incompatibility with 
dika fat. The endothermic profiles of physical 
mixtures of these drugs with dika fat showed peaks 
characteristic of each component. However, some 
of the peaks shifted to either higher or lower 
temperature regions of the thermogram. Drugs such 
as norgestrel and phenobarbital belong to this 
category.   
The third group of drugs showed 
incompatibility with dika fat. The thermal curves of 
1:1 physical mixtures of these drugs with dika fat 
did not represent the curves of the individual 
components. In the physical mixtures of dika fat and 
the drugs, the transition peaks of the drugs were 
obliterated in generated endothermal profiles.  
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Atropine sulphate and ephedrine hydrochloride 
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